NCT03691311UNKNOWNanonymous

An Open Label Biomarker Pilot Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

Sponsor

Source record

Institut Català d'Oncologia

Phase

Source record

EARLY_PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Indication / condition

AI-normalized

Breast Neoplasm Female

Intervention

Source record

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Related intelligence directories

Indication directory: Breast Neoplasm Female Modality directory: small molecule Target directory: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Source & freshness

Source record

NCT ID

NCT03691311

Original source

ClinicalTrials.gov

Source last updated

Nov 03, 2021

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03691311

Title

An Open Label Biomarker Pilot Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

Sponsor

Institut Català d'Oncologia

Status

UNKNOWN

Phase

EARLY_PHASE1

Condition raw

Breast Neoplasm Female, Stage I Breast Cancer, Stage II Breast Cancer, Hormone Receptor Negative Neoplasm, Hormone Receptor Positive Tumor

Condition normalized

Breast Neoplasm Female, Stage I Breast Cancer, Stage II Breast Cancer, Hormone Receptor Negative Neoplasm, Hormone Receptor Positive Tumor

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Target normalized

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Interventions

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Public preview

Source record

This is a biomarker study designed to test the preclinically generated hypothesis of anti-tumoral activity of denosumab in patients with early breast cancer candidates a tumour excision

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open Label Biomarker Pilot Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT03691311

Status

UNKNOWN

Phase

EARLY_PHASE1

Sponsor

Institut Català d'Oncologia

Executive brief

Investment-Ready Snapshot

This is a biomarker study designed to test the preclinically generated hypothesis of anti-tumoral activity of denosumab in patients with early breast cancer candidates a tumour excision

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedNov 03, 2021

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03691311

Indication

Breast Neoplasm Female

Modality

small molecule

Target

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Intervention

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.